RESPIPHARM injekčná suspenzia pre ošípané
RESPIPHARM injekčná suspenzia pre ošípané
Authorised
- Actinobacillus pleuropneumoniae, serovar 2, strain Act 9, Inactivated
- Actinobacillus pleuropneumoniae, serovar 9, strain Act 4, Inactivated
- Actinobacillus pleuropneumoniae, serovar 11, Inactivated
Product identification
Medicine name:
RESPIPHARM injekčná suspenzia pre ošípané
Active substance:
- Actinobacillus pleuropneumoniae, serovar 2, strain Act 9, Inactivated
- Actinobacillus pleuropneumoniae, serovar 9, strain Act 4, Inactivated
- Actinobacillus pleuropneumoniae, serovar 11, Inactivated
Target species:
-
Pig
Route of administration:
-
Intramuscular use
Product details
Active substance and strength:
-
Actinobacillus pleuropneumoniae, serovar 2, strain Act 9, Inactivated
-
Actinobacillus pleuropneumoniae, serovar 9, strain Act 4, Inactivated
-
Actinobacillus pleuropneumoniae, serovar 11, Inactivated
Pharmaceutical form:
-
Suspension for injection
Withdrawal period by route of administration:
-
Intramuscular use
-
Pig
-
All relevant tissues0dayzero days
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI09AB07
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Slovakia
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Pharmagal Bio spol. s r.o.
Marketing authorisation date:
Manufacturing sites for batch release:
- Pharmagal Bio spol. s r.o.
Responsible authority:
- Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
- 97/035/10-S
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
This document does not exist in this language (English). You can find it
in another language below.
Slovak (PDF)
Published on: 3/01/2022